全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

Non-Clinical Factors Associated with International Normalized Ratio Control in Patients on Warfarin Therapy: A Review Paper

DOI: 10.4236/oalib.1106947, PP. 1-21

Subject Areas: Pharmacology

Keywords: Non-Clinical, Risk Factor, International Normalized Ratio, Control, Warfarin

Full-Text   Cite this paper   Add to My Lib

Abstract

Warfarin is a coumarin derivative oral anticoagulant with a narrow therapeutic international normalized ratio (INR) range. Regular and accurate INR monitoring is essential for optimal anticoagulation management and to reduce the risk of adverse events. However, achieving and maintaining the therapeutic INR range are still a challenge as it is affected by several clinical and non-clinical factors. In this review paper, we analyzed how the non-clinical factors like socio-demographic, modifiable risk and protective factors affect the INR control in patients receiving warfarin therapy. We conducted an extensive literature search in Pubmed, Embase, Scopus and Web of Science for original articles or review papers published from 2016 to 2020. Finally, we included 20 articles in this review which fulfilled the selection criteria. Multiple factors such as female gender, ethnicity difference, lower education level, living alone, activities of daily living dependency, smoking, alcohol abuse, fasting and low body mass index along with poor access to medical facilities are associated with poor INR control. Patient self-management and weight elevation are known to be protective factors against poor INR control. Physicians managing patients on warfarin therapy are encouraged to identify and recognize these factors before prescribing warfarin to achieve and maintain the therapeutic INR.

Cite this paper

Ramasamy, T. , Pillai, N. K. , Yap, C. G. and Jahan, N. K. (2020). Non-Clinical Factors Associated with International Normalized Ratio Control in Patients on Warfarin Therapy: A Review Paper. Open Access Library Journal, 7, e6947. doi: http://dx.doi.org/10.4236/oalib.1106947.

References

[1]  Hylek, E.M. (2013) Vitamin K Antagonists and Time in the Therapeutic Range: Implications, Challenges, and Strategies for Improvement. Journal of Thrombosis and Thrombolysis, 35, 333-335. https://doi.org/10.1007/s11239-013-0900-5
[2]  Ruff, C.T., Giugliano, R.P., Braunwald, E., Hoffman, E.B., Deenadayalu, N., Ezekowitz, M.D., Camm, A.J., Weitz, J.I., Lewis, B.S. and Parkhomenko, A. (2014) Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials. The Lancet, 383, 955-962. https://doi.org/10.1016/S0140-6736(13)62343-0
[3]  Jaakkola, S., Nuotio, I., Kiviniemi, T.O., Virtanen, R., Issakoff, M. and Airaksinen, K.E.J. (2017) Incidence and Predictors of Excessive Warfarin Anticoagulation in Patients with Atrial Fibrillation—The EWA Study. PLoS ONE, 12, e0175975. https://doi.org/10.1371/journal.pone.0175975
[4]  Okumura, K., Komatsu, T., Yamashita, T., Okuyama, Y., Harada, M., Konta, Y., Hatayama, T., Horiuchi, D. and Tsushima, E. (2011) Time in the Therapeutic Range during Warfarin Therapy in Japanese Patients with Non-Valvular Atrial Fibrillation. Circulation Journal, 75, 2087-2094. https://doi.org/10.1253/circj.CJ-11-0350
[5]  Palareti, G., Legnani, C., Guazzaloca, G., Lelia, V., Cosmi, B., Lunghi, B., Marchetti, G., Poli, D., Pengo, V. and Clinics, The Ad Hoc Study Group of the Italian Federation of Anticoagulation Clinics (2005) Risks Factors for Highly Unstable Response to Oral Anticoagulation: A Case-Control Study. British Journal of Haematology, 129, 72-78. https://doi.org/10.1111/j.1365-2141.2005.05417.x
[6]  Estes III, N.M., Halperin, J.L., Calkins, H., Ezekowitz, M.D., Gitman, P., Go, A.S., McNamara, R.L., Messer, J.V., Ritchie, J.L. and Romeo, S.J. (2008) ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation). Circulation, 117, 1101-1120. https://doi.org/10.1161/CIRCULATIONAHA.107.187192
[7]  Schmitt, L., Speckman, J. and Ansell, J. (2003) Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range. Journal of Thrombosis and Thrombolysis, 15, 213-216. https://doi.org/10.1023/B:THRO.0000011377.78585.63
[8]  Connolly, S., Pogue, J., Eikelboom, J. and Investigators, A.W. (2008) Benefit of Oral Anticoagulant over Antiplatelet Therapy in AF Depends on the Quality of the INR Control Achieved as Measured by Time in Therapeutic Range. Circulation, 118, 2029-2037. https://doi.org/10.1161/CIRCULATIONAHA.107.750000
[9]  Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., Hindricks, G., Manolis, A.S., Oldgren, J., Popescu, B.A., Schotten, U., Van Putte, B., Vardas, P., Agewall, S., Camm, J., Baron Esquivias, G., Budts, W., Carerj, S., Casselman, F., Coca, A., De Caterina, R., Deftereos, S., Dobrev, D., Ferro, J.M., Filippatos, G., Fitzsimons, D., Gorenek, B., Guenoun, M., Hohnloser, S.H., Kolh, P., Lip, G.Y.H., Manolis, A., McMurray, J., Ponikowski, P., Rosenhek, R., Ruschitzka, F., Savelieva, I., Sharma, S., Suwalski, P., Tamargo, J.L., Taylor, C.J., Van Gelder, I.C., Voors, A.A., Windecker, S., Zamorano, J.L. and Zeppenfeld, K. (2016) 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS. European Heart Journal, 37, 2893-2962. https://doi.org/10.1093/eurheartj/ehw210
[10]  Program, P.S. (2020) Anticoagulation Medication Therapy Adherence Clinic Protocol. Malaysia.
[11]  Atarashi, H., Inoue, H., Okumura, K., Yamashita, T., Kumagai, N. and Origasa, H. (2011) Present Status of Anticoagulation Treatment in Japanese Patients with Atrial Fibrillation: A Report from the J-RHYTHM Registry. Circulation Journal, 75, 1328-1333. https://doi.org/10.1253/circj.CJ-10-1119
[12]  Kakkar, A., Mueller, I., Bassand, J.-P., Fitzmaurice, D., Goldhaber, S., Goto, S., Haas, S., Hacke, W., Lip, G., Mantovani, L., Turpie, A., Misselwitz, F., Rushton-Smith, S., Kayani, G., Wilkinson, P. and Verheugt, F. (2013) Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. PLoS ONE, 8, e63479. https://doi.org/10.1371/journal.pone.0063479
[13]  Kirchhof, P., Ammentorp, B., Darius, H., De Caterina, R., Le Heuzey, J.-Y., Schilling, R.J., Schmitt, J. and Zamorano, J.L. (2014) Management of Atrial Fibrillation in Seven European Countries after the Publication of the 2010 ESC Guidelines on atrial Fibrillation: Primary Results of the Prevention of Thromboemolic Events—European Registry in Atrial Fibrillation (PREFER in AF). EP Europace, 16, 6-14. https://doi.org/10.1093/europace/eut263
[14]  Goudie, B.M., Donnan, P.T., Fairfield, G., Al-Agilly, S.S. and Cachia, P.G. (2004) Dependency Rather than Old Age Increases the Risk of Warfarin-Related Bleeding. The British Journal of General Practice, 54, 690-692.
[15]  Gurwitz, J.H., Avorn, J., Ross-Degnan, D., Choodnovskiy, I. and Ansell, J. (1992) Aging and the Anticoagulant Response to Warfarin Therapy. Annals of Internal Medicine, 116, 901-904. https://doi.org/10.7326/0003-4819-116-11-901
[16]  Shendre, A., Parmar, G.M., Dillon, C., Beasley, T.M. and Limdi, N.A. (2018) Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. Pharmacotherapy, 38, 588-596. https://doi.org/10.1002/phar.2089
[17]  Cohen, J., Wang, J.J., Sinvani, L., Kozikowski, A., Qiu, G., Pekmezaris, R. and Spyropoulos, A.C. (2019) Quality Metrics of Warfarin Initiation in Hospitalized Older Adults. Journal of Thrombosis and Thrombolysis, 48, 459-465. https://doi.org/10.1007/s11239-019-01905-x
[18]  Rose, A.J., Hylek, E.M., Ozonoff, A., Ash, A.S., Reisman, J.I. and Berlowitz, D.R. (2010) Patient Characteristics Associated with Oral Anticoagulation Control: Results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Journal of Thrombosis and Haemostasis, 8, 2182-2191. https://doi.org/10.1111/j.1538-7836.2010.03996.x
[19]  Sandén, P., Renlund, H., Svensson, P.J. and Själander, A. (2015) Warfarin Treatment Complications Do Not Correlate to cTTR When above 70%. Thrombosis Research, 136, 1185-1189. https://doi.org/10.1016/j.thromres.2015.10.031
[20]  Bernaitis, N., Ching, C.K., Teo, S.C., Chen, L., Badrick, T., Davey, A.K., Crilly, J. and Anoopkumar-Dukie, S. (2017) Factors Influencing Warfarin Control in Australia and Singapore. Thrombosis Research, 157, 120-125. https://doi.org/10.1016/j.thromres.2017.07.007
[21]  Abohelaika, S., Wynne, H., Avery, P., Robinson, B., Kesteven, P. and Kamali, F. (2016) Impact of Age on Long-Term Anticoagulation and How Gender and Monitoring Setting Affect It: Implications for Decision Making and Patient Management. British Journal of Clinical Pharmacology, 82, 1076-1083. https://doi.org/10.1111/bcp.13046
[22]  Numao, Y., Suzuki, S., Arita, T., Yagi, N., Otsuka, T., Sagara, K., Semba, H., Sasaki, K., Kano, H., Matsuno, S., Kato, Y., Uejima, T., Oikawa, Y., Nagashima, K., Kirigaya, H., Kunihara, T., Yajima, J., Aizawa, T. and Yamashita, T. (2017) Predictors of International Normalized Ratio Variability in Patients with Atrial Fibrillation Under Warfarin Therapy. Circulation Journal, 82, 39-45. https://doi.org/10.1253/circj.CJ-16-1217
[23]  Van Spall, H.G., Wallentin, L., Yusuf, S., Eikelboom, J.W., Nieuwlaat, R., Yang, S., Kabali, C., Reilly, P.A., Ezekowitz, M.D. and Connolly, S.J. (2012) Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control between Centers and Countries: An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation, 126, 2309-2316. https://doi.org/10.1161/CIRCULATIONAHA.112.101808
[24]  Liang, H.F., Du, X., Zhou, Y.C., Yang, X.Y., Xia, S.J., Dong, J.Z., Lip, G.Y.H. and Ma, C.S. (2019) Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry. Medical Science Monitor, 25, 4691-4698. https://doi.org/10.12659/MSM.917131
[25]  Kooistra, H.A., Gebel, M., Sahin, K., Lensing, A.W. and Meijer, K. (2015) Independent Predictors of Poor Vitamin K Antagonist Control in Venous Thromboembolism Patients. Thrombosis and Haemostasis, 114, 1136-1143. https://doi.org/10.1160/TH14-12-1033
[26]  Apostolakis, S., Sullivan, R.M., Olshansky, B. and Lip, G.Y.H. (2013) Factors Affecting Quality of Anticoagulation Control among Patients with Atrial Fibrillation on Warfarin: The SAMe-TT2R2 Score. Chest, 144, 1555-1563. https://doi.org/10.1378/chest.13-0054
[27]  Dlott, S.J., George, A.R., Huang, W.X., Odeh, M.M., Kaufman, M.H., Ansell, M.J. and Hylek, M.E. (2014) National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation. Circulation, 129, 1407-1414. https://doi.org/10.1161/CIRCULATIONAHA.113.002601
[28]  Schein, J.R., White, C.M., Nelson, W.W., Kluger, J., Mearns, E.S. and Coleman, C.I. (2016) Vitamin K Antagonist Use: Evidence of the Difficulty of Achieving and Maintaining Target INR Range and Subsequent Consequences. Thrombosis Journal, 14, Article No. 14. https://doi.org/10.1186/s12959-016-0088-y
[29]  Prochaska, J.H., Hausner, C., Nagler, M., Gobel, S., Eggebrecht, L., Panova-Noeva, M., Arnold, N., Lauterbach, M., Bickel, C., Michal, M., Hardt, R., Espinola-Klein, C., Lackner, K.J., Munzel, T. and Wild, P.S. (2019) Subtherapeutic Anticoagulation Control under Treatment with Vitamin K-Antagonists-Data from a Specialized Coagulation Service. Thrombosis and Haemostasis, 119, 1347-1357. https://doi.org/10.1055/s-0039-1692175
[30]  Burgess, S., Crown, N., Louzada, M.L., Dresser, G., Kim, R.B. and Lazo-Langner, A. (2013) Clinical Performance of Bleeding Risk Scores for Predicting Major and Clinically Relevant Non-Major Bleeding Events in Patients Receiving Warfarin. Journal of Thrombosis and Haemostasis, 11, 1647-1654. https://doi.org/10.1111/jth.12352
[31]  Nguyen, T., Morel-Kopp, M.-C., Pepperell, D., Cumming, R., Hilmer, S. and Ward, C. (2017) The Impact of Frailty on Coagulation and Responses to Warfarin in Acute Older Hospitalised Patients with Atrial Fibrillation: A Pilot Study. Aging Clinical and Experimental Research, 29, 1129-1138. https://doi.org/10.1007/s40520-017-0733-8
[32]  Fang, M.C., Chang, Y., Hylek, E.M., Rosand, J., Greenberg, S.M., Go, A.S. and Singer, D.E. (2004) Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation. Annals of Internal Medicine, 141, 745-752. https://doi.org/10.7326/0003-4819-141-10-200411160-00005
[33]  Bajorek, B. (2011) A Review of the Safety of Anticoagulants in Older People Using the Medicines Management Pathway: Weighing the Benefits against the Risks. Therapeutic Advances in Drug Safety, 2, 45-58. https://doi.org/10.1177/2042098611400495
[34]  Marie, I., Leprince, P., Menard, J.F., Tharasse, C. and Levesque, H. (2012) Risk Factors of Vitamin K Antagonist Overcoagulation. QJM: An International Journal of Medicine, 105, 53-62.
[35]  Martin-Perez, M., Gaist, D., de Abajo, F.J. and Garcia Rodriguez, L.A. (2019) Predictors of Over-Anticoagulation in Warfarin Users in the UK General Population: A Nested Case-Control Study in a Primary Health Care Database. Thrombosis and Haemostasis, 119, 66-76. https://doi.org/10.1055/s-0038-1676519
[36]  Rose, A.J., Ozonoff, A., Grant, R.W., Henault, L.E. and Hylek, E.M. (2009) Epidemiology of Subtherapeutic Anticoagulation in the United States. Circulation: Cardiovascular Quality and Outcomes, 2, 591-597. https://doi.org/10.1161/CIRCOUTCOMES.109.862763
[37]  Arbring, K., Uppugunduri, S. and Lindahl, T. (2013) Comparison of Prothrombin Time (INR) Results and Main Characteristics of Patients on Warfarin Treatment in Primary Health Care Centers and Anticoagulation Clinics. BMC Health Services Research, 13, Article No. 85. https://doi.org/10.1186/1472-6963-13-85
[38]  Garcia-Sempere, A., Hurtado, I., Bejarano-Quisoboni, D., Rodriguez-Bernal, C., Santa-Ana, Y., Peiro, S. and Sanfelix-Gimeno, G. (2019) Quality of INR Control and Switching to Non-Vitamin K Oral Anticoagulants between Women and Men with Atrial Fibrillation Treated with Vitamin K Antagonists in Spain. A Population-Based, Real-World Study. PLoS ONE, 14, e0211681. https://doi.org/10.1371/journal.pone.0211681
[39]  Gallagher, A.M., Setakis, E., Plumb, J.M., Clemens, A. and van Staa, T.P. (2011) Risks of Stroke and Mortality Associated with Suboptimal Anticoagulation in Atrial Fibrillation Patients. Thrombosis and Haemostasis, 106, 968-977. https://doi.org/10.1160/TH11-05-0353
[40]  Kubo, K., Ohara, M., Tachikawa, M., Cavallari, L.H., Lee, M.T.M., Wen, M.S., Scordo, M.G., Nutescu, E.A., Perera, M.A., Miyajima, A., Kaneko, N., Pengo, V., Padrini, R., Chen, Y.T. and Takahashi, H. (2016) Population Differences in S-Warfarin Pharmacokinetics among African Americans, Asians and Whites: Their Influence on Pharmacogenetic Dosing Algorithms. The Pharmacogenomics Journal, 17, 494-500. https://doi.org/10.1038/tpj.2016.57
[41]  Schwartz, U.I., Ritchie, M.D. and Bradford, Y. (2008) Genetic Determinants of Response to Warfarin during Initial Anticoagulation. Journal of Vascular Surgery, 358, 1372-1373. https://doi.org/10.1016/j.jvs.2008.04.040
[42]  Yong, C., Azarbal, F., Abnousi, F., Heidenreich, P.A., Schmitt, S., Fan, J., Than, C.T., Ullal, A.J., Yang, F., Phibbs, C.S., Frayne, S.M., Ho, P.M., Shore, S., Mahaffey, K.W. and Turakhia, M.P. (2016) Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study). American Journal of Cardiology, 117, 61-68. https://doi.org/10.1016/j.amjcard.2015.09.047
[43]  Limdi, N.A., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D.C., Lee, M.-T.M., Chen, C.-H., Motsinger-Reif, A., Sagreiya, H., Liu, N., Wu, A.H.B., Gage, B.F., Jorgensen, A., Pirmohamed, M., Shin, J.-G., Suarez-Kurtz, G., Kimmel, S.E., Johnson, J.A., Klein, T.E. and Wagner, M.J. (2010) Warfarin Pharmacogenetics: A Single VKORC1 Polymorphism Is Predictive of Dose across 3 Racial Groups. Blood, 115, 3827-3834. https://doi.org/10.1182/blood-2009-12-255992
[44]  Perera, M.A., Gamazon, E., Cavallari, L.H., Patel, S.R., Poindexter, S., Kittles, R.A., Nicolae, D. and Cox, N.J. (2011) The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans. Clinical Pharmacology & Therapeutics, 89, 408-415. https://doi.org/10.1038/clpt.2010.322
[45]  Meschia, F.J., Merrill, Z.P., Soliman, J.E., Howard, M.V., Barrett, A.K., Zakai, A.N., Kleindorfer, A.D., Safford, A.M. and Howard, A.G. (2010) Racial Disparities in Awareness and Treatment of Atrial Fibrillation: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Stroke, 41, 581-587. https://doi.org/10.1161/STROKEAHA.109.573907
[46]  Srivastava, A., Hudson, M., Hamoud, I., Cavalcante, J., Pai, C. and Kaatz, S. (2008) Examining Warfarin Underutilization Rates in Patients with Atrial Fibrillation: Detailed Chart Review Essential to Capture Contraindications to Warfarin Therapy. Thrombosis Journal, 6, Article No. 6. https://doi.org/10.1186/1477-9560-6-6
[47]  Rao, S.R., Reisman, J.I., Kressin, N.R., Berlowitz, D.R., Ash, A.S., Ozonoff, A., Miller, D.R., Hylek, E.M., Zhao, S. and Rose, A.J. (2015) Explaining Racial Disparities in Anticoagulation Control: Results From a Study of Patients at the Veterans Administration. American Journal of Medical Quality, 30, 214-222. https://doi.org/10.1177/1062860614526282
[48]  Limdi, N.A., Brown, T.M., Yan, Q., Thigpen, J.L., Shendre, A., Liu, N., Hill, C.E., Arnett, D.K. and Beasley, T.M. (2015) Race Influences Warfarin Dose Changes Associated with Genetic Factors. Blood, 126, 539-545. https://doi.org/10.1182/blood-2015-02-627042
[49]  Drozda, R.K., Wong, P.S., Patel, A.S., Bress, A.A., Nutescu, H.E., Kittles, H.R. and Cavallari, H.L. (2015) Poor Warfarin Dose Prediction with Pharmacogenetic Algorithms That Exclude Genotypes Important for African Americans. Pharmacogenetics and Genomics, 25, 73-81. https://doi.org/10.1097/FPC.0000000000000108
[50]  Ohara, M., Suzuki, Y., Shinohara, S., Gong, I.Y., Schmerk, C.L., Tirona, R.G., Schwarz, U.I., Wen, M.S., Lee, M.T.M., Mihara, K., Nutescu, E.A., Perera, M.A., Cavallari, L.H., Kim, R.B. and Takahashi, H. (2019) Differences in Warfarin Pharmacodynamics and Predictors of Response among Three Racial Populations. Clinical Pharmacokinetics, 58, 1077-1089. https://doi.org/10.1007/s40262-019-00745-5
[51]  Liu, Y., Jeong, H., Takahashi, H., Drozda, K., Patel, S.R., Shapiro, N.L., Nutescu, E.A. and Cavallari, L.H. (2012) Decreased Warfarin Clearance Associated with the CYP2C9 R150H (*8) Polymorphism. Clinical Pharmacology & Therapeutics, 91, 660-665. https://doi.org/10.1038/clpt.2011.269
[52]  Kimmel, S.E., French, B., Kasner, S.E., Johnson, J.A., Anderson, J.L., Gage, B.F., Rosenberg, Y.D., Eby, C.S., Madigan, R.A. and McBane, R.B. (2013) A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. New England Journal of Medicine, 369, 2283-2293. https://doi.org/10.1056/NEJMoa1310669
[53]  Chalachew, T., Yadeta, D. and Tefera, E. (2019) Factors Associated with Sub-Optimal Control of Anticoagulation in Patients with Prosthetic Heart Valves Taking Oral Anticoagulants in a Sub-Saharan African Setting. Cardiovascular Journal of Africa, 30, 1-5. https://doi.org/10.5830/CVJA-2019-024
[54]  Praxedes, M.F.S., Martins, M.A.P., Mourao, A.O.M., Gomes, K.B., Reis, E.A., Souza, R.P., Campos, E.I.F., Ribeiro, D.D. and Rocha, M.O.C. (2020) Non-Genetic Factors and Polymorphisms in Genes CYP2C9 and VKORC1: Predictive Algorithms for TTR in Brazilian Patients on Warfarin. European Journal of Clinical Pharmacology, 76, 199-209. https://doi.org/10.1007/s00228-019-02772-4
[55]  Tani, Y., Kondo, N., Takagi, D., Saito, M., Hikichi, H., Ojima, T. and Kondo, K. (2015) Combined Effects of Eating Alone and Living Alone on Unhealthy Dietary Behaviors, Obesity and Underweight in Older Japanese Adults: Results of the JAGES. Appetite, 95, 1-8. https://doi.org/10.1016/j.appet.2015.06.005
[56]  Sconce, E., Khan, T., Mason, J., Noble, F., Wynne, H. and Kamali, F. (2005) Patients with Unstable Control Have a Poorer Dietary Intake of Vitamin K Compared to Patients with Stable Control of Anticoagulation. Thrombosis and Haemostasis, 93, 872-875. https://doi.org/10.1160/TH04-12-0773
[57]  Nathisuwan, S., Dilokthornsakul, P., Chaiyakunapruk, N., Morarai, T., Yodting, T. and Piriyachananusorn, N. (2011) Assessing Evidence of Interaction between Smoking and Warfarin: A Systematic Review and Meta-Analysis. Chest, 139, 1130-1139. https://doi.org/10.1378/chest.10-0777
[58]  Al-Momany, N.H., Makahleh, Z.M., Al-Omari, N.A., Al-Sarayreh, H.A. and Momani, R.O. (2019) Analysis of Factors That Interrupt with INR Control in the First Anticoagulation Clinic Monitoring Jordanian Patients. Clinical and Applied Thrombosis/Hemostasis, 25. https://doi.org/10.1177/1076029619870252
[59]  Bourgeois, S., Jorgensen, A., Zhang, E.J., Hanson, A., Gillman, M.S., Bumpstead, S., Toh, C.H., Williamson, P., Daly, A.K., Kamali, F., Deloukas, P. and Pirmohamed, M. (2016) A Multi-Factorial Analysis of Response to Warfarin in a UK Prospective Cohort. Genome Medicine, 8, Article No. 2. https://doi.org/10.1186/s13073-015-0255-y
[60]  Reddy, U., Mallepaddi, N.R. and Chevassut, T.J. (2015) High INR on Warfarin. BMJ, 350, h1282. https://doi.org/10.1136/bmj.h1282
[61]  Hirsh, J., Dalen, J.E., Anderson, D.R., Poller, L., Bussey, H., Ansell, J. and Deykin, D. (2001) Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range. Chest, 119, 8S-21S. https://doi.org/10.1378/chest.119.1_suppl.8S
[62]  Bjorck, F., Kadhim, H. and Sjalander, A. (2019) Predictors for INR-Control in a Well-Managed Warfarin Treatment Setting. Journal of Thrombosis and Thrombolysis, 47, 227-232. https://doi.org/10.1007/s11239-018-1765-4
[63]  Pisters, R., Lane, D.A., Nieuwlaat, R., De Vos, C.B., Crijns, H.J. and Lip, G.Y. (2010) A Novel User-Friendly Score (HAS-BLED) to Assess 1-Year Risk of Major Bleeding in Patients with Atrial Fibrillation: The Euro Heart Survey. Chest, 138, 1093-1100. https://doi.org/10.1378/chest.10-0134
[64]  Singer, D.E., Hellkamp, A.S., Piccini, J.P., Mahaffey, K.W., Lokhnygina, Y., Pan, G., Halperin, J.L., Becker, R.C., Breithardt, G., Hankey, G.J., Hacke, W., Nessel, C.C., Patel, M.R., Califf, R.M., Fox, K.A.A. and ROCKET AF Investigators (2013) Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data from the ROCKET AF Clinical Trial. Journal of the American Heart Association, 2, e000067. https://doi.org/10.1161/JAHA.112.000067
[65]  Lammers, L.A., Achterbergh, R., de Vries, E.M., van Nierop, F.S., Klümpen, H.-J., Soeters, M.R., Boelen, A., Romijn, J.A. and Mathôt, R.A.A. (2015) Short-Term Fasting Alters Cytochrome P450-Mediated Drug Metabolism in Humans. Drug Metabolism and Disposition, 43, 819-828. https://doi.org/10.1124/dmd.114.062299
[66]  Lammers, L.A., Achterbergh, R., van Schaik, R.H.N.., Romijn, J.A. and Mathôt, R.A.A. (2017) Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach. Clinical Pharmacokinetics, 56, 1231-1244. https://doi.org/10.1007/s40262-017-0515-7
[67]  Lai, Y.F., Cheen, M.H.H., Lim, S.H., Yeo, F.H.I., Nah, S.C., Kong, M.C., Mya, D., Lee, L.H. and Ng, H.J. (2014) The Effects of Fasting in Muslim Patients Taking Warfarin. Journal of Thrombosis and Haemostasis, 12, 349-354. https://doi.org/10.1111/jth.12496
[68]  Katada, Y., Nakagawa, S., Nishimura, A., Sato, Y.K., Taue, H., Matsumura, K., Yamazaki, K., Minakata, K., Yano, I., Omura, T., Imai, S., Yonezawa, A., Sato, Y., Nakagawa, T., Minatoya, K. and Matsubara, K. (2019) Effects of Fasting on Warfarin Sensitivity Index in Patients Undergoing Cardiovascular Surgery. European Journal of Clinical Pharmacology, 75, 561-568. https://doi.org/10.1007/s00228-018-2592-4
[69]  Konishi, H., Eguchi, Y., Fujii, M., Saotome, T., Sasaki, T., Takahashi, K., Sudo, M., Morii, H., Minouchi, T. and Yamaji, A. (2004) Unusual Hypersensitivity to Warfarin in a Critically Ill Patient. Journal of Clinical Pharmacy and Therapeutics, 29, 485-490. https://doi.org/10.1111/j.1365-2710.2004.00583.x
[70]  Leandro-Merhi, V. and de Aquino, J. (2014) Determinants of Malnutrition and Post-Operative Complications in Hospitalized Surgical Patients. Journal of Health, Population and Nutrition, 32, 400-410.
[71]  Penning-van Beest, F.J.A., Geleijnse, J.M., van Meegen, E., Vermeer, C., Rosendaal, F.R. and Stricker, B.H.C. (2002) Lifestyle and Diet as Risk Factors for Overanticoagulation. Journal of Clinical Epidemiology, 55, 411-417. https://doi.org/10.1016/S0895-4356(01)00485-1
[72]  Baron, J.A., Mann, J. and Stukel, T. (1989) Effect of Weight Loss on Coagulation Factors VII and X. The American Journal of Cardiology, 64, 519-522. https://doi.org/10.1016/0002-9149(89)90432-3
[73]  Bodenheimer, T., Lorig, K., Holman, H. and Grumbach, K. (2002) Patient Self-Management of Chronic Disease in Primary Care. JAMA, 288, 2469-2475. https://doi.org/10.1001/jama.288.19.2469
[74]  Bloomfield, H.E., Krause, A., Greer, N., Taylor, B.C., MacDonald, R., Rutks, I., Reddy, P. and Wilt, T.J. (2011) Meta-Analysis: Effect of Patient Self-Testing and Self-Management of Long-Term Anticoagulation on Major Clinical Outcomes. Annals of Internal Medicine, 154, 472-482. https://doi.org/10.7326/0003-4819-154-7-201104050-00005
[75]  Garcia-Alamino, J.M., Ward, A.M., Alonso-Coello, P., Perera, R., Bankhead, C., Fitzmaurice, D. and Heneghan, C.J. (2010) Self-Monitoring and Self-Management of Oral Anticoagulation. The Cochrane Database of Systematic Reviews, No. 4, CD003839. https://doi.org/10.1002/14651858.CD003839.pub2
[76]  Medical Advisory Secretariat (2009) Point-of-Care International Normalized Ratio (INR) Monitoring Devices for Patients on Long-Term Oral Anticoagulation Therapy: An Evidence-Based Analysis. Ontario Health Technology Assessment Series, 9, 1-114. https://pubmed.ncbi.nlm.nih.gov/23074516 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377545/
[77]  Cryder, B., Felczak, M., Darkwa, A., Patel, H., Janociak, J. and Rihani, R. (2017) Transition of Stable Patients from Traditional Anticoagulation Clinic Services to Telephonic Management. International Journal of Clinical Pharmacy and Pharmaceutical Care, 39, 569-572. https://doi.org/10.1007/s11096-017-0428-4
[78]  Nagler, M., Bachmann, L.M., Schmid, P., Muller, P.R. and Wuillemin, W.A. (2014) Patient Self-Management of Oral Anticoagulation with Vitamin K Antagonists in Everyday Practice: Efficacy and Safety in a Nationwide Long-Term Prospective Cohort Study. PLoS ONE, 9, e95761. https://doi.org/10.1371/journal.pone.0095761
[79]  Ansell, J., Jacobson, A., Levy, J., Völler, H. and Hasenkam, J.M. (2005) Guidelines for Implementation of Patient Self-Testing and Patient Self-Management of Oral Anticoagulation. International Consensus Guidelines Prepared by International Self-Monitoring Association for Oral Anticoagulation. International Journal of Cardiology, 99, 37-45. https://doi.org/10.1016/j.ijcard.2003.11.008
[80]  Schaefer, C., Wuillemin, W.A., Kessels, A., Jacobson, A. and Nagler, M. (2016) Predictors of Anticoagulation Quality in 15834 Patients Performing Patient Self-Management of Oral Anticoagulation with Vitamin K Antagonists in Real-Life Practice: A Survey of the International Self-Monitoring Association of Orally Anticoagulated Patients. British Journal of Haematology, 175, 677-685. https://doi.org/10.1111/bjh.14273
[81]  Grunau, B.E., Wiens, M.O. and Harder, K.K. (2011) Patient Self-Management of Warfarin Therapy: Pragmatic Feasibility Study in Canadian Primary Care. Canadian Family Physician, 57, e292-e298.
[82]  Ansell, J.E. (1999) Empowering Patients to Monitor and Manage Oral Anticoagulation Therapy. JAMA, 281, 182-183. https://doi.org/10.1001/jama.281.2.182
[83]  Christensen, T.D., Johnsen, S.P., Hjortdal, V.E. and Hasenkam, J.M. (2007) Self-Management of Oral Anticoagulant Therapy: A Systematic Review and Meta-Analysis. International Journal of Cardiology, 118, 54-61. https://doi.org/10.1016/j.ijcard.2006.06.018
[84]  Heneghan, C., Ward, A. and Perera, R. (2012) Self-Monitoring of Oral Anticoagulation: Systematic Review and Meta-Analysis of Individual Patient Data. The Lancet, 379, 322-334. https://doi.org/10.1016/S0140-6736(11)61294-4
[85]  Ward, A., Tompson, A., Fitzmaurice, D., Sutton, S., Perera, R. and Heneghan, C. (2015) Cohort Study of Anticoagulation Self-Monitoring (CASM): A Prospective Study of Its Effectiveness in the Community. The British Journal of General Practice, 65, e428-e437. https://doi.org/10.3399/bjgp15X685633

Full-Text


comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413